Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandu PharmaceuticalsBOM:524703 -4.17%70 Quick Ratio is 1.42 as of Mar. 2026, which is 49% above its 10-year median of 0.95. GuruFocus rates BOM:524703 with a GF Score™ of 70/100 and a GF Value™ of ₹58.58 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 998 Drug Manufacturers companies, Sandu Pharmaceuticals ranks worse than 50.8% on this metric.
Sandu Pharmaceuticals has a quick ratio of 1.42. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sandu Pharmaceuticals's Quick Ratio or its related term are showing as below:
BOM:524703'
s Quick Ratio Range Over the Past 10 Years
Min: 0.49 Med: 0.95 Max: 1.55
Current: 1.42
During the past 13 years, Sandu Pharmaceuticals's highest Quick Ratio was 1.55. The lowest was 0.49. And the median was 0.95.
BOM:524703's Quick Ratio is ranked worse than 50.8% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs BOM:524703: 1.42
Sandu Pharmaceuticals (BOM:524703) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Sandu Pharmaceuticals Quick Ratio Related Terms
Sandu Pharmaceuticals Quick Ratio Historical Data
* Premium members only.
The historical data trend for Sandu Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sandu Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandu Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandu Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Sandu Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Sandu Pharmaceuticals's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandu Pharmaceuticals (BOM:524703) has a Quick Ratio of 1.42 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sandu Pharmaceuticals and its competitors. This is 49% above median its historical median of 0.95. Over the past decade, Sandu Pharmaceuticals' Quick Ratio has ranged from 0.49 to 1.55. According to the industry distribution chart, Sandu Pharmaceuticals ranks #507 out of 998 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Sandu Pharmaceuticals' Quick Ratio too high?
Sandu Pharmaceuticals' current Quick Ratio of 1.42 is 49% above median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 1.55. The Drug Manufacturers industry median Quick Ratio is 1.45. Sandu Pharmaceuticals' value of 1.42 is 2.1% below this industry median. Based on the distribution chart, Sandu Pharmaceuticals ranks #507 out of 998 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandu Pharmaceuticals has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sandu Pharmaceuticals' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandu Pharmaceuticals ranks #507 out of 998 companies for Quick Ratio. This places Sandu Pharmaceuticals in the lower half of its industry. The industry median Quick Ratio is 1.45. Sandu Pharmaceuticals' value of 1.42 is 2.1% below this benchmark. Historically, Sandu Pharmaceuticals' own Quick Ratio has ranged from 0.49 to 1.55 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 1.45, Sandu Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandu Pharmaceuticals's current Quick Ratio of 1.42 is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sandu Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandu Pharmaceuticals's current Quick Ratio is 1.42, which is 49% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandu Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sandu Pharmaceuticals (BOM:524703) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹58.58, compared to a current price of ₹39.29 — trading 32.9% below its estimated fair value. The current Quick Ratio is 1.42, which is 49% above median its 10-year median of 0.95 and 2.1% below the Drug Manufacturers industry median of 1.45. Sandu Pharmaceuticals' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Sandu Pharmaceuticals (BOM:524703), the current Quick Ratio is 1.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandu Pharmaceuticals (BOM:524703) Overvalued in 2026?
Based on GuruFocus' analysis, Sandu Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹39.29 is trading 32.9% below its estimated GF Value™ of ₹58.58.
GuruFocus considers Sandu Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for BOM:524703:
Quick Ratio: 1.42 (49% above median its 10-year median of 0.95)
GF Value™: ₹58.58 vs. price of ₹39.29 (32.9% below fair value)
Industry Position: 2.1% below the Drug Manufacturers median (#507 of 998)
No single metric tells the full story. See the BOM:524703 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524703 has been successfully added to your 
